Phase 2 Endometrial Cancer Trial, Recruiting NCT06522828 Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT06522828
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 75 years old
  • People who have been diagnosed with advanced endometrial cancer or platinum-resistant ovarian cancer (a type of ovarian cancer that has stopped responding to platinum-based chemotherapy)
  • People who have a good general level of physical functioning, rated 0 or 1 on a standard medical scale (meaning able to carry out daily activities with little or no limitation)
  • People whose life expectancy is 12 weeks or longer
  • People who have signed a form giving their informed consent to participate

Who may not be able to join:

  • People who have cancer that has spread to the brain or central nervous system in a way that is uncontrolled or causing symptoms
  • People who are still experiencing significant side effects (rated above Grade 1, other than hair loss or tiredness) from any previous cancer treatment
  • People whose organ function or bone marrow function is not working at an adequate level
  • People who are pregnant or currently breastfeeding
  • People who are known to have an allergy, sensitivity, or intolerance to the study drug SSGJ-707

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13708384529

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Registry
ClinicalTrials.gov
Start date
10 October 2024
Est. completion
1 August 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ORR; Safety and tolerability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov